| mavrilimumab (KPL-301) / Kiniksa |
Kiniksa_COVID-002: Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia |
|
|
| Recruiting | 2 | 6 | Italy | mavrilimumab (KPL-301) - Kiniksa | Kiniksa Pharmaceuticals Ltd. | Coronavirus, Severe COVID-19 Pneumonia | | | | |
NCT04337216: Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation |
|
|
| Not yet recruiting | 2 | 10 | US | Mavrilimumab | Virginia Commonwealth University | COVID-19 | 08/20 | 08/20 | | |
NCT04492514: Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation |
|
|
| Recruiting | 2 | 60 | US | Mavrilimumab, KPL-301, Placebo, Control | Kristin Hudock, Kiniksa Pharmaceuticals, Ltd. | COVID 19, SARS-CoV 2, Pneumonia | 05/21 | 05/21 | | |
| vixarelimab (RG6536) / Roche |
| Completed | 2 | 190 | Europe, Canada, US, RoW | vixarelimab, KPL-716, Placebo | Kiniksa Pharmaceuticals, Ltd. | Prurigo Nodularis, Pruritis | 12/22 | 08/23 | | |
NCT06137183: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) |
|
|
| Recruiting | 2 | 210 | Europe, US, RoW | Vixarelimab, RO7622888; KPL-716, Placebo | Genentech, Inc. | Ulcerative Colitis | 09/26 | 05/27 | | |
NCT05785624: A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease |
|
|
| Recruiting | 2 | 320 | Europe, Canada, US, RoW | Vixarelimab, RO7622888, KPL-716, Placebo | Genentech, Inc. | Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement | 04/27 | 08/27 | | |
| abiprubart (KPL-404) / Kiniksa |
2022-000169-42: Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis |
|
|
| Not yet recruiting | 2 | 131 | Europe, RoW | KPL-404, Solution for injection | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Rheumatoid arthritis (RA), Rheumatoid arthritis (RA), Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT05198310: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, Placebo | Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
NCT06531395: A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants with Sjögren's Disease |
|
|
| Recruiting | 2 | 200 | US | Abiprubart, KPL-404, Placebo | Kiniksa Pharmaceuticals International, plc, Kiniksa Pharmaceuticals, GmbH | Sjögrens Disease | 12/26 | 07/27 | | |
